LeMaitre Vascular, Inc. $LMAT Shares Bought by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in LeMaitre Vascular, Inc. by 34.5%, purchasing an additional 60,438 shares and bringing its total holdings to 235,436 shares valued at approximately $19.75 million.
• LeMaitre Vascular's stock experienced a slight decline of 0.3%, with a current market opening at $96.45 and an overall market cap of $2.18 billion.
• The company announced a quarterly dividend of $0.20 per share to be paid on September 4th, representing an annualized dividend yield of 0.8% and a payout ratio of 38.83%.

Invesco Ltd. raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 34.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,436 shares of the medical instruments supplier's stock after buying an additional 60,438 shares during the period. Invesco Ltd. owned about 1.04% of LeMaitre Vascular worth $19,753,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the first quarter worth about $26,000. NBC Securities Inc. purchased a new position in shares of LeMaitre Vascular during the first quarter worth about $36,000. US Bancorp DE grew its holdings in shares of LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of LeMaitre Vascular by 112.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock worth $157,000 after purchasing an additional 900 shares during the last quarter. Finally, Blueshift Asset Management LLC purchased a new position in shares of LeMaitre Vascular during the first quarter worth about $232,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insider Activity

In related news, Director John A. Roush sold 6,561 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the sale, the director owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Roberts sold 10,815 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 in the last three months. 9.50% of the stock is currently owned by company insiders.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $0.40 during midday trading on Wednesday, reaching $95.68. 133,643 shares of the company were exchanged, compared to its average volume of 220,077. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The stock has a fifty day simple moving average of $86.86 and a 200 day simple moving average of $86.43. The stock has a market cap of $2.17 billion, a P/E ratio of 46.45, a PEG ratio of 2.45 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The firm had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business's revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be given a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 38.83%.

Wall Street Analysts Forecast Growth

LMAT has been the topic of several research reports. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald raised their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.